The percentages of patients with unchanged , increased , and decreased antiglaucoma ophthalmic solution use during the study period were 61.1 % ( 55/90 ) , 17.8 % ( 16/90 ) , and 3.3 % ( 3/90 ) , respectively , in the NIA group , and 56.8 % ( 46/81 ) , 8.6 % ( 7/81 ) , and 13.6 % ( 11/81 ) , respectively , in the IA group ( P < .001 ) .